NurExone Biologic (TSXV:NRX) Total Stockholders Equity : C$2.51 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Total Stockholders Equity?

NurExone Biologic's Total Stockholders Equity for the quarter that ended in Dec. 2024 was C$2.51 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. NurExone Biologic's Book Value per Share for the quarter that ended in Dec. 2024 was C$0.04. The ratio of a company's debt over equity can be used to measure how leveraged this company is. NurExone Biologic's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.02.

NurExone Biologic Total Stockholders Equity Historical Data

The historical data trend for NurExone Biologic's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Total Stockholders Equity Chart

NurExone Biologic Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

1.51

2.85

0.25

2.51

NurExone Biologic Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial										0.25	4.92	3.53	3.97	2.51

NurExone Biologic (TSXV:NRX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

NurExone Biologic's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(2.509	-	0)	/	71.074
	=	0.04

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

NurExone Biologic's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.003	+	0.044)	/	2.509
	=	0.02

NurExone Biologic Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

NRXBF:USA J90:Germany

Address

1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website

https://www.nurexone.com

NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.

Executives

James Angus Wilson (bilkstys-) Richardson

10% Security Holder, Director, Senior Officer

NurExone Biologic Headlines

No Headlines